1. Home
  2. RVSN vs GLTO Comparison

RVSN vs GLTO Comparison

Compare RVSN & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

HOLD

Current Price

$0.38

Market Cap

20.9M

Sector

N/A

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$28.92

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSN
GLTO
Founded
2016
2011
Country
Israel
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
23.7M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
RVSN
GLTO
Price
$0.38
$28.92
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
734.0K
113.4K
Earning Date
02-03-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$776,000.00
N/A
Revenue This Year
$28.46
N/A
Revenue Next Year
$755.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$2.01
52 Week High
$2.72
$33.60

Technical Indicators

Market Signals
Indicator
RVSN
GLTO
Relative Strength Index (RSI) 51.79 63.43
Support Level $0.33 $24.53
Resistance Level $0.37 $30.03
Average True Range (ATR) 0.03 3.62
MACD 0.00 -0.31
Stochastic Oscillator 55.94 65.71

Price Performance

Historical Comparison
RVSN
GLTO

About RVSN Rail Vision Ltd.

Rail Vision Ltd is a development-stage technology company that is engaged in the design, development, and assembly of railway detection systems designed to solve the challenges in railway operational safety, efficiency, and predictive maintenance. Its railway detection systems include different types of cameras, including optics, visible light spectrum cameras (video), and thermal cameras that transmit data to a ruggedized onboard computer which is designed to be suitable for the rough environment of a train's locomotive. It has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: